|
**Overview**: Interleukin-6 Plus Panel**Introduction**: The Interleukin-6 Plus Panel is a diagnostic tool designed for comprehensive inflammatory screening using serum samples. In India, cytokine profiling (IL-6, CRP, TNF-alpha) is crucial in sepsis, autoimmune flares (RA, SLE), post-COVID sequelae, and malignancy-associated inflammation, guiding prognosis and targeted therapy. High morbidity from under-testing in rural/low-SES critically ill patients, limited cytokine labs, delayed anti-cytokine therapy leading to multi-organ dysfunction. Per immunology practices aligned with ICMR and Indian Society of Critical Care Medicine guidelines, the test employs immunoassay for IL-6, CRP, and TNF-alpha over 1-2 days with high accuracy, valuable for assessing cytokine storm severity and treatment response. This diagnostic falls under inflammatory screening and targets patients with sepsis, autoimmune disease, or critical illness, addressing accurate detection to guide tocilizumab, steroids, or supportive care. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise multi-cytokine evaluation and reducing inflammatory mortality. Its serum-based approach ensures reliable biomarker quantification.**Other Names**: IL-6 Plus Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Multi-cytokine panel standard; in India, expanded in ICU settings.**Purpose**: The test assesses 3 parameters including IL-6 level to guide comprehensive inflammatory screening, assess cytokine profile, inform therapy.**Test Parameters**: 1. IL-6 Level, 2. CRP, 3. TNF-alpha.**Pretest Condition**: No fasting required; patients should report systemic inflammation or critical illness.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on fever, organ failure, autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected cytokine storm including mortality, benefits of profiling, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or acute phase variation can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated IL-6/CRP/TNF-alpha indicates severe inflammation, necessitating specialist input.**Specialist Consultation**: Intensivists or rheumatologists should be consulted for management.**Additional Supporting Tests**: Procalcitonin, ferritin for confirmation.**Test Limitations**: Nonspecific markers; comprehensive approach required.**References**: Indian Journal of Critical Care Medicine 2024, Inflammation Studies India 2023. |
